Literature DB >> 25779638

A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice.

Néstor Rubio-Infante1, Dania O Govea-Alonso, Andrea Romero-Maldonado, Ana Lilia García-Hernández, Damaris Ilhuicatzi-Alvarado, Jorge A Salazar-González, Schuyler S Korban, Sergio Rosales-Mendoza, Leticia Moreno-Fierros.   

Abstract

Multi-HIV, a multiepitopic protein derived from both gp120 and gp41 envelope proteins of the human immunodeficiency virus (HIV), has been proposed as a vaccine prototype capable of inducing broad immune responses, as it carries various B and T cell epitopes from several HIV strains. In this study, the immunogenic properties of a Multi-HIV expressed in tobacco chloroplasts are evaluated in test mice. BALB/c mice orally immunized with tobacco-derived Multi-HIV have elicited antibody responses, including both the V3 loop of gp120 and the ELDKWA epitope of gp41. Based on splenocyte proliferation assays, stimulation with epitopes of the C4, V3 domain of gp120, and the ELDKWA domain of gp41 elicits positive cellular responses. Furthermore, specific interferon gamma production is observed in both CD4+ and CD8+ T cells stimulated with HIV peptides. These results demonstrate that plant-derived Multi-HIV induces T helper-specific responses. Altogether, these findings illustrate the immunogenic potential of plant-derived Multi-HIV in an oral immunization scheme. The potential of this low-cost immunization approach and its implications on HIV/AIDS vaccine development are discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25779638     DOI: 10.1007/s12033-015-9856-3

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  50 in total

Review 1.  The role of IFN-gamma in immune responses to viral infections of the central nervous system.

Authors:  David A Chesler; Carol Shoshkes Reiss
Journal:  Cytokine Growth Factor Rev       Date:  2002-12       Impact factor: 7.638

2.  Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.

Authors:  Barton F Haynes; Benjiang Ma; David C Montefiori; Terri Wrin; Christos J Petropoulos; Laura L Sutherland; Richard M Scearce; Cathrine Denton; Shi-Mao Xia; Bette T Korber; Hua-Xin Liao
Journal:  Virology       Date:  2005-10-20       Impact factor: 3.616

3.  Binding analysis of 95 HIV gp120 peptides to HLA-DR1101 and -DR0401 evidenced many HLA-class II binding regions on gp120 and suggested several promiscuous regions.

Authors:  P Gaudebout; D Zeliszewski; J J Golvano; C Pignal; S Le Gac; F Borras-Cuesta; G Sterkers
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-02-01

4.  Kinetics and specificities of the T helper-cell response to gp120 in the asymptomatic stage of HIV-1 infection.

Authors:  A M Geretti; C A Van Baalen; J C Borleffs; C A Van Els; A D Osterhaus
Journal:  Scand J Immunol       Date:  1994-04       Impact factor: 3.487

5.  A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection.

Authors:  Li Lu; Senthilkumar Palaniyandi; Rongyu Zeng; Yu Bai; Xindong Liu; Yunsheng Wang; C David Pauza; Derry C Roopenian; Xiaoping Zhu
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

7.  A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

Authors:  Nobuyuki Matoba; Aude Magérus; Brian C Geyer; Yunfang Zhang; Mrinalini Muralidharan; Annette Alfsen; Charles J Arntzen; Morgane Bomsel; Tsafrir S Mor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-03       Impact factor: 11.205

Review 8.  Green factories for biopharmaceuticals.

Authors:  S Melnik; E Stoger
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

9.  A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Authors:  Hanna C Kelker; Vincenza R Itri; Fred T Valentine
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

10.  Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease.

Authors:  Jung Won Youm; Jae Heung Jeon; Hee Kim; Young Ho Kim; Kisung Ko; Hyouk Joung; Hyunsoon Kim
Journal:  Biotechnol Lett       Date:  2008-07-05       Impact factor: 2.461

View more
  8 in total

Review 1.  Edible plants for oral delivery of biopharmaceuticals.

Authors:  Matilde Merlin; Mario Pezzotti; Linda Avesani
Journal:  Br J Clin Pharmacol       Date:  2016-05-09       Impact factor: 4.335

Review 2.  Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases.

Authors:  Henry Daniell; Hui-Ting Chan; Elise K Pasoreck
Journal:  Annu Rev Genet       Date:  2016-10-21       Impact factor: 16.830

Review 3.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

Review 4.  Using transgenic plants and modified plant viruses for the development of treatments for human diseases.

Authors:  Hwei-San Loh; Brian J Green; Vidadi Yusibov
Journal:  Curr Opin Virol       Date:  2017-08-08       Impact factor: 7.090

Review 5.  Plant-Derived Recombinant Vaccines against Zoonotic Viruses.

Authors:  Gergana Zahmanova; Katerina Takova; Rumyana Valkova; Valentina Toneva; Ivan Minkov; Anton Andonov; Georgi L Lukov
Journal:  Life (Basel)       Date:  2022-01-21

Review 6.  Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

Authors:  Mohammad Tahir Waheed; Muhammad Sameeullah; Faheem Ahmed Khan; Tahira Syed; Manzoor Ilahi; Johanna Gottschamel; Andreas Günter Lössl
Journal:  Springerplus       Date:  2016-01-22

Review 7.  The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.

Authors:  Young Hee Joung; Se Hee Park; Ki-Beom Moon; Jae-Heung Jeon; Hye-Sun Cho; Hyun-Soon Kim
Journal:  Int J Mol Sci       Date:  2016-10-13       Impact factor: 5.923

Review 8.  Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development.

Authors:  Balamurugan Shanmugaraj; Ashwini Malla; Waranyoo Phoolcharoen
Journal:  Pathogens       Date:  2020-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.